Report Detail

Request for Sample of this report

Pharma & Healthcare Global Non-small Cell Lung Cancer Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM4607604
    • |
  • 13 August, 2024
    • |
  • Global
    • |
  • 90 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Non-small Cell Lung Cancer Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Non-small Cell Lung Cancer Drugs industry chain, the market status of Lung Adenocarcinoma (Biologics, Small Molecule Targeted Therapy), Squamous Cell Lung Carcinoma (Biologics, Small Molecule Targeted Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Non-small Cell Lung Cancer Drugs.
Regionally, the report analyzes the Non-small Cell Lung Cancer Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Non-small Cell Lung Cancer Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Non-small Cell Lung Cancer Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Non-small Cell Lung Cancer Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Biologics, Small Molecule Targeted Therapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Non-small Cell Lung Cancer Drugs market.
Regional Analysis: The report involves examining the Non-small Cell Lung Cancer Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Non-small Cell Lung Cancer Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Non-small Cell Lung Cancer Drugs:
Company Analysis: Report covers individual Non-small Cell Lung Cancer Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Non-small Cell Lung Cancer Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Adenocarcinoma, Squamous Cell Lung Carcinoma).
Technology Analysis: Report covers specific technologies relevant to Non-small Cell Lung Cancer Drugs. It assesses the current state, advancements, and potential future developments in Non-small Cell Lung Cancer Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Non-small Cell Lung Cancer Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Non-small Cell Lung Cancer Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other
Market segment by Application
Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma
Market segment by players, this report covers
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Non-small Cell Lung Cancer Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Non-small Cell Lung Cancer Drugs, with revenue, gross margin and global market share of Non-small Cell Lung Cancer Drugs from 2019 to 2024.
Chapter 3, the Non-small Cell Lung Cancer Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Non-small Cell Lung Cancer Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Non-small Cell Lung Cancer Drugs.
Chapter 13, to describe Non-small Cell Lung Cancer Drugs research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Non-small Cell Lung Cancer Drugs
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Non-small Cell Lung Cancer Drugs by Type
    • 1.3.1 Overview: Global Non-small Cell Lung Cancer Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Non-small Cell Lung Cancer Drugs Consumption Value Market Share by Type in 2023
    • 1.3.3 Biologics
    • 1.3.4 Small Molecule Targeted Therapy
    • 1.3.5 Chemotherapy
    • 1.3.6 Other
  • 1.4 Global Non-small Cell Lung Cancer Drugs Market by Application
    • 1.4.1 Overview: Global Non-small Cell Lung Cancer Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Lung Adenocarcinoma
    • 1.4.3 Squamous Cell Lung Carcinoma
    • 1.4.4 Large-cell Lung Carcinoma
  • 1.5 Global Non-small Cell Lung Cancer Drugs Market Size & Forecast
  • 1.6 Global Non-small Cell Lung Cancer Drugs Market Size and Forecast by Region
    • 1.6.1 Global Non-small Cell Lung Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Non-small Cell Lung Cancer Drugs Market Size by Region, (2019-2030)
    • 1.6.3 North America Non-small Cell Lung Cancer Drugs Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Non-small Cell Lung Cancer Drugs Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size and Prospect (2019-2030)
    • 1.6.6 South America Non-small Cell Lung Cancer Drugs Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Non-small Cell Lung Cancer Drugs Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 AstraZeneca
    • 2.1.1 AstraZeneca Details
    • 2.1.2 AstraZeneca Major Business
    • 2.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Product and Solutions
    • 2.1.4 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 AstraZeneca Recent Developments and Future Plans
  • 2.2 Bristol-Myers Squibb Company
    • 2.2.1 Bristol-Myers Squibb Company Details
    • 2.2.2 Bristol-Myers Squibb Company Major Business
    • 2.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product and Solutions
    • 2.2.4 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
  • 2.3 Eli Lilly and Company
    • 2.3.1 Eli Lilly and Company Details
    • 2.3.2 Eli Lilly and Company Major Business
    • 2.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product and Solutions
    • 2.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.4 F. Hoffmann-La Roche Ltd
    • 2.4.1 F. Hoffmann-La Roche Ltd Details
    • 2.4.2 F. Hoffmann-La Roche Ltd Major Business
    • 2.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product and Solutions
    • 2.4.4 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
  • 2.5 Merck & Co., Inc.
    • 2.5.1 Merck & Co., Inc. Details
    • 2.5.2 Merck & Co., Inc. Major Business
    • 2.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product and Solutions
    • 2.5.4 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Merck & Co., Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Non-small Cell Lung Cancer Drugs Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Non-small Cell Lung Cancer Drugs by Company Revenue
    • 3.2.2 Top 3 Non-small Cell Lung Cancer Drugs Players Market Share in 2023
    • 3.2.3 Top 6 Non-small Cell Lung Cancer Drugs Players Market Share in 2023
  • 3.3 Non-small Cell Lung Cancer Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Non-small Cell Lung Cancer Drugs Market: Region Footprint
    • 3.3.2 Non-small Cell Lung Cancer Drugs Market: Company Product Type Footprint
    • 3.3.3 Non-small Cell Lung Cancer Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Non-small Cell Lung Cancer Drugs Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Non-small Cell Lung Cancer Drugs Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Non-small Cell Lung Cancer Drugs Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Non-small Cell Lung Cancer Drugs Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Non-small Cell Lung Cancer Drugs Consumption Value by Type (2019-2030)
  • 6.2 North America Non-small Cell Lung Cancer Drugs Consumption Value by Application (2019-2030)
  • 6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Country
    • 6.3.1 North America Non-small Cell Lung Cancer Drugs Consumption Value by Country (2019-2030)
    • 6.3.2 United States Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Non-small Cell Lung Cancer Drugs Consumption Value by Type (2019-2030)
  • 7.2 Europe Non-small Cell Lung Cancer Drugs Consumption Value by Application (2019-2030)
  • 7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Country
    • 7.3.1 Europe Non-small Cell Lung Cancer Drugs Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 7.3.3 France Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Consumption Value by Region (2019-2030)
    • 8.3.2 China Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 8.3.5 India Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Non-small Cell Lung Cancer Drugs Consumption Value by Type (2019-2030)
  • 9.2 South America Non-small Cell Lung Cancer Drugs Consumption Value by Application (2019-2030)
  • 9.3 South America Non-small Cell Lung Cancer Drugs Market Size by Country
    • 9.3.1 South America Non-small Cell Lung Cancer Drugs Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Non-small Cell Lung Cancer Drugs Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Non-small Cell Lung Cancer Drugs Market Drivers
  • 11.2 Non-small Cell Lung Cancer Drugs Market Restraints
  • 11.3 Non-small Cell Lung Cancer Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Non-small Cell Lung Cancer Drugs Industry Chain
  • 12.2 Non-small Cell Lung Cancer Drugs Upstream Analysis
  • 12.3 Non-small Cell Lung Cancer Drugs Midstream Analysis
  • 12.4 Non-small Cell Lung Cancer Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Non-small Cell Lung Cancer Drugs. Industry analysis & Market Report on Non-small Cell Lung Cancer Drugs is a syndicated market report, published as Global Non-small Cell Lung Cancer Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Non-small Cell Lung Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,634.36
    		3,951.54
    		5,268.72
    		3,132.00
    		4,698.00
    		6,264.00
    		494,682.00
    		742,023.00
    		989,364.00
    		291,380.40
    		437,070.60
    		582,760.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo